The single blood draw that has shaped American men’s health more than any other arrived in clinical practice in the late 1980s and was approved by the FDA for monitoring prostate cancer in 1986, then for screening in 1994. The PSA test measures prostate-specific antigen, a protein produced almost entirely by prostate cells, and remains the cornerstone of prostate cancer detection and follow-up despite decades of debate over how it should be used.
What PSA Actually Is
Prostate-specific antigen is a glycoprotein enzyme that liquefies semen. It is produced by both normal and cancerous prostate cells, which is why elevated values are not specific to cancer. The National Cancer Institute notes that PSA can rise with BPH, prostatitis, urinary tract infection, recent ejaculation, vigorous bicycling, and digital rectal exam.
Total PSA is most commonly measured. Free PSA, the unbound fraction, helps refine risk when total PSA falls between 4 and 10 ng/mL. Lower free-to-total percentages suggest higher cancer probability. Newer markers including the 4Kscore, Prostate Health Index (PHI), and urine-based assays add additional discrimination.
Reference Ranges and Age-Adjusted Values
The traditional cutoff of 4.0 ng/mL evolved from early validation studies, but it is increasingly viewed as a starting point rather than a hard line. Many urologists use age-adjusted ranges: under 2.5 for men in their 40s, under 3.5 in their 50s, under 4.5 in their 60s, and under 6.5 in their 70s. Population-based norms suggest median PSA values are around 0.7 ng/mL in men aged 40 to 49, climbing gradually with age.
Lower values do not guarantee absence of cancer. The Prostate Cancer Prevention Trial showed that men with PSA below 4 still had cancer detected on biopsy in a meaningful share of cases, with higher rates as PSA approached 4. The traditional binary view (above or below 4) has given way to risk-based thinking that incorporates age, prior PSA values, family history, race, and clinical findings.
Beyond the Single Number: Density, Velocity, and Free PSA
PSA density divides total PSA by prostate volume measured on imaging. A PSA density above 0.15 ng/mL/cc raises concern for clinically significant cancer, while lower density values reassure when PSA is mildly elevated due to a large gland. Density is particularly useful in men with BPH.
PSA velocity tracks changes over time. A rise greater than 0.75 ng/mL per year, or 0.35 ng/mL per year when starting from a low baseline, is more concerning than a stable elevated value. Free PSA percentage helps in the gray zone. Free fractions below 10 percent suggest higher cancer risk; values above 25 percent are reassuring.
The AUA 2023 early detection guideline incorporates these refinements rather than relying on the single 4.0 cutoff.
Preparation for the Test
Most labs accept PSA samples without strict fasting requirements. Many clinicians ask men to avoid ejaculation for 48 hours and intense cycling for 24 to 48 hours before testing. Recent prostate biopsy can elevate PSA for weeks. Active urinary tract infection or prostatitis should resolve before screening levels are interpreted. Some medications, particularly 5-alpha reductase inhibitors like finasteride and dutasteride used for BPH, lower PSA roughly 50 percent over 6 to 12 months. Clinicians typically double the measured value to estimate the “true” PSA in men on these drugs.
What Results Mean and Next Steps
A normal PSA does not require immediate action beyond following the screening schedule discussed in the prostate cancer screening guide. An elevated PSA usually prompts a repeat test in 6 to 12 weeks to confirm, sometimes with antibiotic treatment if prostatitis is suspected.
If PSA stays elevated, secondary tests refine risk: free PSA percentage, 4Kscore, PHI, or urine-based markers. Many practices now perform multiparametric prostate MRI before biopsy. Lesions scored PI-RADS 3 to 5 prompt targeted biopsy. Negative MRI reduces but does not eliminate the chance of clinically significant cancer.
For monitoring known prostate cancer, PSA after definitive treatment should fall to near zero (after surgery) or reach a stable nadir (after radiation). Rising PSA after treatment indicates biochemical recurrence and triggers further imaging including PSMA PET.
Limitations of the Test
PSA is sensitive but not specific. Most men with mildly elevated PSA do not have cancer. Among men with PSA between 4 and 10 ng/mL who undergo biopsy, roughly 70 to 75 percent are negative. PSA also misses some cancers entirely, particularly higher-grade tumors that produce relatively little PSA.
Screening with PSA reduces prostate cancer mortality modestly but contributes to overdiagnosis of indolent tumors. The number needed to screen and number needed to diagnose to prevent one death has narrowed in recent years as MRI-first pathways and active surveillance reduce the overtreatment cascade.
When to See a Doctor
Most healthy men aged 50 and over (45 for African American men or those with a strong family history) benefit from a discussion about PSA testing with their primary care physician. Men with new urinary symptoms, blood in the urine or semen, bone pain, or unexplained weight loss should seek evaluation regardless of recent PSA values.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience high fever above 101 degrees Fahrenheit with chills after a prostate biopsy, signs of sepsis, inability to urinate, or sudden severe back pain with leg weakness in the setting of known prostate cancer.
Frequently Asked Questions
How often should I get a PSA test?
The interval depends on baseline value, age, and risk factors. The 2023 AUA guideline suggests every 2 to 4 years for men with low baseline PSA, with shorter intervals as values approach the abnormal range. Discuss timing with your clinician.
Does a PSA above 4 mean I have cancer?
No. About 25 to 30 percent of men with PSA between 4 and 10 ng/mL who proceed to biopsy have cancer detected. Most elevated values reflect BPH, prostatitis, or other benign conditions.
Can I lower my PSA naturally?
Some lifestyle changes (weight loss, treating prostatitis, avoiding ejaculation before testing) modestly affect PSA. The goal of testing is detecting underlying disease, not chasing a number, so lowering PSA without addressing its cause does not change outcomes.
What is PSMA and how does it differ from PSA?
PSMA is prostate-specific membrane antigen, a different protein expressed on prostate cancer cells. PSMA PET imaging detects cancer cells throughout the body and is used in staging and recurrence rather than as a blood test.
The Bottom Line
The PSA test is a useful but imperfect tool, and the way it is used has become considerably more sophisticated than the simple over-or-under-4 framework most men remember. Modern interpretation incorporates age-adjusted ranges, density, velocity, free PSA, and emerging biomarkers, often paired with multiparametric MRI before biopsy. The single PSA number is the start of a conversation with your clinician, not the end of one.